The importance of CheckMate 025 lies in its demonstration that nivolumab improved overall survival (OS) compared to the standard treatment, everolimus. This trial has provided strong evidence that immunotherapy can be more beneficial than traditional treatments for certain patients with advanced kidney cancer, paving the way for new treatment protocols.
